The company has substantially boosted its progress of a new solution for ATTR-CM, leveraging the compound. Initial patient data suggests promising benefits for individuals diagnosed by the serious condition. This effort https://bridgebio755017.blue-blogs.com/50406203/bridgebio-advances-amyloidosis-therapy-using-the-therapy